Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors.
Jacob JM, Woldu SL, Linehan J, Labbate C, Rose KM, Sexton WJ, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour SB, Quek ML, Johnson B, O'Donnell M, Eisner BH, Feldman AS, Murray KS, Matin SF, Lotan Y, Dickstein RJ. Jacob JM, et al. Among authors: tachibana i. Urol Oncol. 2024 Jan;42(1):20.e17-20.e23. doi: 10.1016/j.urolonc.2023.07.004. Epub 2023 Jul 28. Urol Oncol. 2024. PMID: 37517898
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Woldu SL, Labbate C, Murray KS, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour S, Quek ML, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y. Woldu SL, et al. Among authors: tachibana i. Urol Oncol. 2023 Mar;41(3):147.e15-147.e21. doi: 10.1016/j.urolonc.2022.10.029. Epub 2022 Nov 22. Urol Oncol. 2023. PMID: 36424224
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Labbate C, Woldu S, Murray K, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner B, Feldman A, Lotan Y, Matin SF. Labbate C, et al. Among authors: tachibana i. J Urol. 2023 May;209(5):872-881. doi: 10.1097/JU.0000000000003185. Epub 2023 Jan 19. J Urol. 2023. PMID: 36657029
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Kaimakliotis HZ, Tachibana I, Woldu S, Labbate C, Jacob J, Murray K, Rose K, Sexton W, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Matin SF, Lotan Y, Feldman AS. Kaimakliotis HZ, et al. Among authors: tachibana i. Urol Oncol. 2023 Sep;41(9):387.e1-387.e7. doi: 10.1016/j.urolonc.2023.04.010. Epub 2023 May 26. Urol Oncol. 2023. PMID: 37246135
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.
Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, Sexton WJ, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Cazzaniga W, Nicol D, Gerdtsson A, Tandstad T, Fizazi K, Fankhauser CD; EAU-YAU Penile and Testis Cancer Working Group. Antonelli L, et al. Among authors: tachibana i. J Clin Oncol. 2023 Dec 1;41(34):5296-5305. doi: 10.1200/JCO.23.00443. Epub 2023 Sep 1. J Clin Oncol. 2023. PMID: 37656935
181 results